| 臺大學術典藏 |
2019 |
Real-world effectiveness and safety of glecaprevir/pibrentasvir in Asian patients with chronic hepatitis C
|
Hsu S.-J.; Chiu M.-C.; Fang Y.-J.; Yang T.-H.; Yu J.-J.; CHIEH-CHANG CHEN; Kuo C.-C.; Lee J.-Y.; Chen C.-H.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-02-22T05:34:12Z |
Real-world effectiveness and safety of glecaprevir/pibrentasvir in Asian patients with chronic hepatitis C
|
Hsu S.-J.; Chiu M.-C.; Fang Y.-J.; Yang T.-H.; Yu J.-J.; Chen C.-C.; Kuo C.-C.; Lee J.-Y.; CHIEN-HUNG CHEN; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-02-14T06:28:47Z |
Real-world effectiveness and safety of glecaprevir/pibrentasvir in Asian patients with chronic hepatitis C
|
Hsu S.-J.; Chiu M.-C.; YU-JEN FANG; Yang T.-H.; Yu J.-J.; Chen C.-C.; Kuo C.-C.; Lee J.-Y.; Chen C.-H.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-02-18T08:25:58Z |
Real-world effectiveness and safety of glecaprevir/pibrentasvir in Asian patients with chronic hepatitis C
|
Hsu S.-J.; Chiu M.-C.; Fang Y.-J.; Yang T.-H.; Yu J.-J.; CHIEH-CHANG CHEN; Kuo C.-C.; Lee J.-Y.; Chen C.-H.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-02-23T02:12:23Z |
Real-world effectiveness and safety of glecaprevir/pibrentasvir in Asian patients with chronic hepatitis C
|
Hsu S.-J.; Chiu M.-C.; Fang Y.-J.; Yang T.-H.; Yu J.-J.; Chen C.-C.; Kuo C.-C.; Lee J.-Y.; CHIEN-HUNG CHEN; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-09-04T05:16:49Z |
Real-world effectiveness and safety of glecaprevir/pibrentasvir in Asian patients with chronic hepatitis C
|
Hsu S.-J.; Chiu M.-C.; Fang Y.-J.; Yang T.-H.; Yu J.-J.; Chen C.-C.; Kuo C.-C.; Lee J.-Y.; Chen C.-H.; Chen D.-S.; JIA-HORNG KAO |
| 國立成功大學 |
2020-03-01 |
Real-world effectiveness and safety of ledipasvir/sofosbuvir for genotype 6 chronic hepatitis C patients in Taiwan
|
鄭斌男; 陳志州;李佩倫;邱宏志;董宏達;邱彥程 |
| 國立成功大學 |
2020-03 |
Real-world effectiveness and safety of ledipasvir/sofosbuvir for genotype 6 chronic hepatitis C patients in Taiwan
|
Chen;Jyh-Jou;Lee;Pei-Lun;Chiu;Hung-Chih;Tung;Hung-Da;Chiu;Yen-Cheng;Cheng;Pin-Nan |
| 臺大學術典藏 |
2021-05-24T07:20:28Z |
Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan
|
CHEN-HUA LIU; Liu C.-J.; Su T.-H.; Yang H.-C.; Hong C.-M.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-06-25T08:10:15Z |
Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan
|
Liu C.-H.; Liu C.-J.; Su T.-H.; Yang H.-C.; CHUN-MING HONG; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-07-03T03:33:40Z |
Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan
|
Liu C.-H.; Liu C.-J.; Su T.-H.; Yang H.-C.; Hong C.-M.; Tseng T.-C.; PEI-JER CHEN; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-07-12T02:44:33Z |
Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan
|
Liu C.-H; | Liu C.-J; | Su T.-H; | HUNG-CHIH YANG; | Hong C.-M; | Tseng T.-C; | Chen P.-J; | Chen D.-S; | Kao J.-H. |
| 臺大學術典藏 |
2021-09-04T05:17:09Z |
Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan
|
Liu C.-H.; Liu C.-J.; Su T.-H.; Yang H.-C.; Hong C.-M.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2022-01-24T09:31:21Z |
Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan
|
Liu C.-H.; CHUN-JEN LIU; Su T.-H.; Yang H.-C.; Hong C.-M.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-03-09T01:43:23Z |
Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan
|
Liu C.-H.; Liu C.-J.; TUNG-HUNG SU; Yang H.-C.; Hong C.-M.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2019-02-27T06:48:01Z |
Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan
|
Tseng, Tai-Chung;JIA-HORNG KAO;DING-SHINN CHEN;PEI-JER CHEN;CHUN-MING HONG;HUNG-CHIH YANG;TUNG-HUNG SU;CHUN-JEN LIU;CHEN-HUA LIU; CHEN-HUA LIU; CHUN-JEN LIU; TUNG-HUNG SU; HUNG-CHIH YANG; CHUN-MING HONG; Tseng, Tai-Chung; PEI-JER CHEN; DING-SHINN CHEN; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-03-09T01:43:20Z |
Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan
|
Liu C.-H.; Liu C.-J.; TUNG-HUNG SU; Yang H.-C.; Hong C.-M.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-05-24T07:20:25Z |
Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan
|
CHEN-HUA LIU; Liu C.-J.; Su T.-H.; Yang H.-C.; Hong C.-M.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-06-25T08:10:13Z |
Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan
|
Liu C.-H.; Liu C.-J.; Su T.-H.; Yang H.-C.; CHUN-MING HONG; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-07-12T02:44:29Z |
Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan
|
Liu C.-H; | Liu C.-J; | Su T.-H; | HUNG-CHIH YANG; | Hong C.-M; | Tseng T.-C; | Chen P.-J; | Chen D.-S; | Kao J.-H. |
| 臺大學術典藏 |
2021-09-04T05:16:58Z |
Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan
|
Liu C.-H.; Liu C.-J.; Su T.-H.; Yang H.-C.; Hong C.-M.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2022-01-24T09:31:17Z |
Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan
|
Liu C.-H.; CHUN-JEN LIU; Su T.-H.; Yang H.-C.; Hong C.-M.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-07-03T03:33:35Z |
Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan
|
Liu C.-H.; Liu C.-J.; Su T.-H.; Yang H.-C.; Hong C.-M.; Tseng T.-C.; PEI-JER CHEN; Chen D.-S.; Kao J.-H. |
| 國立成功大學 |
2019-05 |
Real-world effectiveness and safety of sofosbuvir plus daclatasvir with or without ribavirin for genotype 2 chronic hepatitis C in Taiwan
|
Cheng;Pin-Nan;Chiu;Yen-Cheng;Chien;Shih-Chieh;Chiu;Hung-Chih |
| 國立成功大學 |
2022-11 |
Real-world effectiveness and safety of sofosbuvir/velpatasvir and glecaprevir/ pibrentasvir for genotype 6 chronic hepatitis C
|
Chen;Jyh-Jou;Chiu;Yen-Cheng;Lee;Pei-Lun;Tung;Hung-Da;Chiu;Hung-Chih;Chien;Shih-Chieh;Cheng;Pin-Nan |
